<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852719</url>
  </required_header>
  <id_info>
    <org_study_id>MYR 301</org_study_id>
    <secondary_id>2019-001213-17</secondary_id>
    <nct_id>NCT03852719</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)</brief_title>
  <official_title>A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of bulevirtide for treatment&#xD;
      of CHD in comparison to delayed treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Actual">November 26, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Response at Week 48: Percentage of Participants with Undetectable (&lt; LoD) Hepatitis Delta Virus Ribonucleic Acid (HDV RNA) or Decrease by ≥ 2 log10 IU/ml From Baseline and ALT Normalization</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Undetectable HDV RNA at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ALT Normalization at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Undetectable HDV RNA 24 Weeks after Scheduled End of Treatment (Sustained Virological Response)</measure>
    <time_frame>Posttreatment Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Undetectable HDV RNA 48 Weeks after Scheduled End of Treatment (Sustained Virological Response)</measure>
    <time_frame>Posttreatment Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Liver Stiffness as Measured by Elastography at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Liver Stiffness as Measured by Elastography at Week 96</measure>
    <time_frame>Baseline, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Liver Stiffness as Measured by Elastography at Week 144</measure>
    <time_frame>Baseline, Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Liver Stiffness as Measured by Elastography at Week 192</measure>
    <time_frame>Baseline, Week 192</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Liver Stiffness as Measured by Elastography at Weeks 240</measure>
    <time_frame>Baseline, Week 240</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Permanently Discontinue Study Drug due to an Adverse Event</measure>
    <time_frame>Up to 144 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Chronic Hepatitis Delta</condition>
  <arm_group>
    <arm_group_label>Delayed Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive delayed treatment with bulevirtide 10 mg/day subcutaneously (SC) for 96 weeks after an observational period of 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bulevirtide 2 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive bulevirtide 2 mg/day SC for 144 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bulevirtide 10 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive bulevirtide 10 mg/day SC for 144 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bulevirtide</intervention_name>
    <description>Administered via SC injections</description>
    <arm_group_label>Bulevirtide 10 mg/day</arm_group_label>
    <arm_group_label>Bulevirtide 2 mg/day</arm_group_label>
    <arm_group_label>Delayed Treatment</arm_group_label>
    <other_name>Myrcludex B</other_name>
    <other_name>Hepcludex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form.&#xD;
&#xD;
          2. Positive serum anti-hepatitis delta virus (HDV) antibody results or polymerase chain&#xD;
             reaction (PCR) results for serum/ plasma HDV ribonucleic acid (RNA) for at least 6&#xD;
             months before screening.&#xD;
&#xD;
          3. Positive PCR results for serum/plasma HDV RNA at screening.&#xD;
&#xD;
          4. Alanine transaminase level &gt; 1 x upper limit of normal (ULN), but less than 10 x ULN.&#xD;
&#xD;
          5. Serum albumin &gt; 28 g/L.&#xD;
&#xD;
          6. Negative urine pregnancy test for females of childbearing potential.&#xD;
&#xD;
          7. Inclusion criteria for females:&#xD;
&#xD;
               -  Postmenopausal for at least 2 years, or&#xD;
&#xD;
               -  Surgically sterile (total hysterectomy or bilateral oophorectomy, bilateral tubal&#xD;
                  ligation, staples, or another type of sterilization), or&#xD;
&#xD;
               -  Abstinence from heterosexual intercourse throughout the study, or&#xD;
&#xD;
               -  Willingness to use highly effective contraception (double barrier method or&#xD;
                  barrier contraception in combination with hormonal or intrauterine contraceptive)&#xD;
                  throughout the study and for 3 months after the last dose of the study medication&#xD;
                  for participants discontinued during the treatment period.&#xD;
&#xD;
          8. Individuals must agree to use a highly effective contraception (double barrier method&#xD;
             or barrier contraception in combination with hormonal or intrauterine contraceptive&#xD;
             used by female partners) and not to donate sperm throughout the study and for 3 months&#xD;
             after the last dose of the study medication for participants discontinued during the&#xD;
             treatment period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Child-Pugh hepatic insufficiency score over 7 points. Uncomplicated oesophageal&#xD;
             varices allowed; Individuals with current bleeding or ligation, or history of bleeding&#xD;
             or ligation within the last 2 years are excluded.&#xD;
&#xD;
          2. Hepatitis C virus (HCV) or uncontrolled human immunodeficiency virus (HIV)&#xD;
             coinfection. Individuals with HCV antibodies can be enrolled, if screening HCV RNA&#xD;
             test is negative. Individuals with HIV infection can be enrolled if cluster of&#xD;
             differentiation (CD4+) cell counts are &gt;500/mL and HIV RNA is below limit of detection&#xD;
             for at least 12 months.&#xD;
&#xD;
          3. Creatinine clearance &lt; 60 mL/min as estimated using Cockcroft-Gault formula.&#xD;
&#xD;
          4. Total bilirubin ≥ 34.2 µmol/L. (Participants with higher total bilirubin values may be&#xD;
             included after the consultation with the Study Medical Monitor, if such elevation can&#xD;
             be clearly attributed to Gilbert's syndrome associated with low-grade&#xD;
             hyperbilirubinemia.)&#xD;
&#xD;
          5. Evidence of an active or suspected malignancy or a history of malignancy, or an&#xD;
             untreated pre-malignancy disorder within the last 5 years (with the exception of&#xD;
             successfully treated carcinoma of the cervix in situ and successfully treated basal&#xD;
             cell carcinoma and squamous cell carcinoma not less than 1 year prior to screening&#xD;
             [and no more than 3 excised skin cancer within the last 5 years prior to screening])&#xD;
             or history of hepatic carcinoma.&#xD;
&#xD;
          6. Systemic connective tissue disorders.&#xD;
&#xD;
          7. New York Heart Association (NYHA) class III-IV congestive heart failure.&#xD;
&#xD;
          8. Participants with uncontrolled arterial hypertension: systolic blood pressure &gt; 150 mm&#xD;
             Hg and/ or diastolic blood pressure &gt; 100 mm Hg at Screening.&#xD;
&#xD;
          9. Previous or unstable concurrent diseases or conditions that prevent individual's&#xD;
             enrolment into the study.&#xD;
&#xD;
         10. Participants with mental disorders or social circumstances that preclude them from&#xD;
             following protocol requirements.&#xD;
&#xD;
         11. Current or previous (within last 2 years) decompensated liver disease, including&#xD;
             coagulopathy, hepatic encephalopathy and esophageal varices hemorrhage.&#xD;
&#xD;
         12. One or more additional known primary or secondary causes of liver disease, other than&#xD;
             hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic&#xD;
             involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other&#xD;
             congenital or metabolic conditions affecting the liver, congestive heart failure or&#xD;
             other severe cardiopulmonary disease, etc.). Gilbert's syndrome, a benign disorder&#xD;
             associated with low-grade hyperbilirubinemia, will not exclude patients from&#xD;
             participation in this trial. Autoimmune hepatitis stigmata attributed to HDV infection&#xD;
             in the opinion of the investigator are allowed.&#xD;
&#xD;
         13. White blood cells (WBC) count &lt; 3000 cells/mm^3 (&lt;1500 if African participants).&#xD;
&#xD;
         14. Neutrophil count &lt; 1500 cells/mm^3 (&lt;1000 if African participants).&#xD;
&#xD;
         15. Platelet count &lt; 60,000 cells/mm^3.&#xD;
&#xD;
         16. Use of prohibited psychotropic agents at Screening.&#xD;
&#xD;
         17. Use of interferons within 6 months before Screening.&#xD;
&#xD;
         18. History of solid organ transplantation.&#xD;
&#xD;
         19. Current alcohol abuse or alcohol abuse within 6 months prior to enrolment in this&#xD;
             study; past or current drug addict.&#xD;
&#xD;
         20. History of disease requiring regular use of systemic glucocorticosteroids (inhalative&#xD;
             glucocorticosteroids are allowed) or other immunosuppressants.&#xD;
&#xD;
         21. Pregnant or breast-feeding females.&#xD;
&#xD;
         22. Participation in another clinical study with investigational drugs within 30 days&#xD;
             prior to randomization.&#xD;
&#xD;
         23. Receipt of bulevirtide previously, e.g. in clinical trials.&#xD;
&#xD;
         24. Inability to follow protocol requirements and undergo all protocol procedures. NOTE:&#xD;
             Participants with medical contraindication for liver biopsy are allowed to participate&#xD;
             in this study. Such participants will exempt from liver biopsy requirements in this&#xD;
             study.&#xD;
&#xD;
        Individuals receiving prohibited treatment at Screening cannot be included into the study&#xD;
        unless this treatment is withdrawn prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine, an administrative unit of New York University, an education corporation</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University Well Madical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AoR), Klinik für Gastroenterologie und Hepatologie</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Medizinische Klinik 1</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Hospital, Departament of Gastroenterology, Infectious Diseases, Intoxication</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Modena e Reggio Emilia- Ospedale Civile S.</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Epatologia - Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;South Ural State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized clinical Infectious diseases Hospital</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Budget Institution of Science &quot;Central Research Institute of Epidemiology&quot; of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC&quot;Clinic of Modern Medicine&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Scientific and Research Clinical Institute</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Company &quot;Hepatolog&quot;</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Hospital</name>
      <address>
        <city>Stavropol'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge, Dept of Infectious Diseases</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <disposition_first_submitted>November 12, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>November 12, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 17, 2021</disposition_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

